Navigation Links
Researchers use DNA to build tool that may literally shine light on cancer
Date:5/7/2014

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

The researchers' nanosensor measures pH variations at the nanoscale how acidic (a higher pH level) or alkaline (a lower pH level) it is. Many biomolecules, such as enzymes and proteins, are strongly regulated by small pH changes. These changes affect in turn biological activities such as enzyme catalysis, protein assembly, membrane function and cell death. There is also a strong relation between cancer and pH.

Cancer cells often display a lower pH compared to normal cells: the pH level inside cancer cells is higher than it is outside. "In living organisms, these small pH changes typically occur in tiny areas measuring only few hundred nanometers," says senior author Prof. Francesco Ricci. "Developing sensors or nanomachines that can measure pH changes at this scale should prove of utility for several applications in the fields of in-vivo imaging, clinical diagnostics and drug-delivery."

"DNA represents an ideal material to build sensors or nanomachines at the nanometer scale" says senior author Prof. Valle-Blisle. "By taking advantage of a specific DNA sequences that form pH-sensitive triple helix, we have designed a versatile nanosensor that can be programmed to fluoresce only at specific pH values." Fluorescence is the emission of radiation, including visible light, caused by an exchange of energy. "This programming ability represents a key feature for clinical applications we can design a specific sensor to send a fluorescent signal only when the pH reaches a specific value which is, for example, characteristic of a specific disease," adds first author Andrea Idili.

In the future, this recently patented nanotechnology may also find applications in the development of novel drug-delivery platforms that release chemio-therapeutic drugs only in the viscinity of tumor cells.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-566-3813
University of Montreal
Source:Eurekalert  

Related medicine news :

1. Sleep researchers at SRI International identify promising new treatment for narcolepsy
2. Chimpanzees show similar personality traits to humans, Georgia State researchers say
3. Researchers present findings on promising biomarker for esophageal cancer
4. Bioinformatics approach helps researchers find new uses for old drug
5. BrightFocus honors 5 vision researchers
6. Researchers link age, general health and antidepressant use with eye disorders
7. Researchers granted funding to explore novel lung cancer strategies
8. MS researchers find brain & cognitive reserve protect long-term against cognitive decline
9. UNC researchers discover master regulator role for little-known protein in cancer cells
10. CWRU researchers profile womens employment, caregiving workloads, effort and health
11. Drug monitoring information improves regimen adherence, Carnegie Mellon researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers use DNA to build tool that may literally shine light on cancer
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: